Asthma during pregnancy in a population-based study--pregnancy complications and adverse perinatal outcomes by Rejnö, Gustaf et al.
Asthma during Pregnancy in a Population-Based Study -
Pregnancy Complications and Adverse Perinatal
Outcomes
Gustaf Rejno¨1,2*, Cecilia Lundholm1, Tong Gong1, Kjell Larsson3, Sissel Saltvedt4,5, Catarina Almqvist1,6
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 2Obstetrics and Gynaecology Unit, So¨dersjukhuset, Stockholm,
Sweden, 3 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Clinical Science and Education, So¨dersjukhuset, Karolinska
Institutet, Stockholm, Sweden, 5Obstetrics and Gynaecology Unit, Karolinska University Hospital, Stockholm, Sweden, 6Astrid Lindgren Children’s Hospital, Lung and
Allergy Unit, Karolinska University Hospital, Stockholm, Sweden
Abstract
Background: Asthma is one of the most common chronic diseases, and prevalence, severity and medication may have an
effect on pregnancy. We examined maternal asthma, asthma severity and control in relation to pregnancy complications,
labour characteristics and perinatal outcomes.
Methods: We retrieved data on all singleton births from July 1, 2006 to December 31, 2009, and prescribed drugs and
physician-diagnosed asthma on the same women from multiple Swedish registers. The associations were estimated with
logistic regression.
Results: In total, 266 045 women gave birth to 284 214 singletons during the study period. Maternal asthma was noted in 26
586 (9.4%) pregnancies. There was an association between maternal asthma and increased risks of pregnancy complications
including preeclampsia or eclampsia (adjusted OR 1.15; 95% CI 1.06–1.24) and premature contractions (adj OR 1.52; 95% CI
1.29–1.80). There was also a significant association between maternal asthma and emergency caesarean section (adj OR
1.29; 95% CI 1.23–1.34), low birth weight, and small for gestational age (adj OR 1.23; 95% CI 1.13–1.33). The risk of adverse
outcomes such as low birth weight increased with increasing asthma severity. For women with uncontrolled compared to
those with controlled asthma the results for adverse outcomes were inconsistent displaying both increased and decreased
OR for some outcomes.
Conclusion: Maternal asthma is associated with a number of serious pregnancy complications and adverse perinatal
outcomes. Some complications are even more likely with increased asthma severity. With greater awareness and proper
management, outcomes would most likely improve.
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Introduction
Asthma is one of the most common chronic diseases with
reported prevalence between 3.7 and 8.4% [1,2]. Asthma
symptoms may increase during pregnancy which can be attribut-
able either to worsening of asthma due to the pregnancy itself or
inadequate medication [3,4]. Maternal asthma has been associated
with an increased risk for pregnancy complications such as
preeclampsia, gestational diabetes, premature contractions and
premature ruptures of membranes [5–8]. Maternal asthma has
also been associated with an increased prevalence of labour
characteristics including caesarean section and placental abruption
[9–12], or perinatal outcomes such as low birth weight,
prematurity and small for gestational age (SGA) [6,12–15] but
studies are also non-consistent [2,7,16].
According to GINA (Global Initiative for Asthma) guidelines
[17], asthma can be classified into mild, moderate and severe and
symptoms should be treated with medication in a step-wise
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approach to obtain asthma control. Mild and moderate well-
controlled asthma is generally associated with uncomplicated
pregnancy and delivery [8]. More importantly, severe asthma and
poor asthma control seem to increase the risk of preterm delivery,
low birth weight and small for gestational age (SGA) [18]. Yet, not
all studies have reported increased risks of perinatal complications
with severe asthma and poor control. A recent meta-analysis
suggested that this discrepancy might be caused by variation in
study size and that participation in smaller prospective studies is
associated with better disease control and therefore better
outcomes [19]. It is of great importance that midwives and
obstetricians identify pregnant women at risk of adverse outcomes
due to asthma. Thus, there is a call for larger studies to assess the
effect of maternal asthma, severity and control on pregnancy
complications, labour and perinatal outcomes.
Findings on the effect of maternal asthma on pregnancy and
delivery outcomes in population-based cohorts compiled from
registers offers many advantages including powerful assessment of
the association between asthma in pregnant women and
pregnancy complications or adverse outcomes, with control for
important confounders and the effect of medication usage. By
using information on asthma diagnosis from different sources and
prescribed drugs as a proxy for disease it is possible to obtain
objective measures of exposure. Indices developed to assess the
severity and control of asthma can be used in epidemiological
studies [20,21].
The principal aim of this study was to assess possible
associations between maternal asthma, pregnancy and labour
characteristics and adverse perinatal outcomes. We also aimed to
assess the effect of asthma severity and control on pregnancy
complications and perinatal outcomes.
Materials and Methods
Study design and population
The Swedish National Board of Health and Welfare holds a
number of registers covering health information. The universal use
of the Personal Identity Number (PIN), a unique identifier for each
resident, enables unambiguous linkage to these registers and those
held by Statistics Sweden [22]. We conducted a population-based
cohort study using the four Swedish national registers held by the
Swedish National Board of Health and Welfare and Statistics
Sweden.
All women in Sweden who started their pregnancy after July 1
2006, bore singletons and gave birth at the latest 31 December
2009 were identified through the Medical Birth Register, which
includes data on pregnancy and perinatal characteristics for
approximately 99% of all births, after pregnancy week 22, in
Sweden since 1973 [23]. The cohort was linked to the Prescribed
Drug Register which contains all prescribed drugs dispensed at
pharmacies in Sweden since July 1, 2005 [24], the National
Patient Register which covers all in-patient care in Sweden from
1987 and 75% of all outpatient visits since 2001. Information on
socioeconomic status including cohabitation and level of education
was retrieved from the Longitudinal integration database for
health insurance and labour market studies (LISA by Swedish
acronym), held by Statistics Sweden.
We included only singletons since multiple pregnancies exhibit
many different characteristics compared to singletons.
Variables
Maternal characteristics. Maternal age and body mass
index (BMI in kg/m2), calculated from height and weight, were
retrieved from the Medical Birth Register. Other background
characteristics from the same source were parity, smoking, country
of birth, cohabitation. Variables on maternal age and parity were
recorded at delivery whereas maternal smoking habits, height and
weight were registered at the first visit to the antenatal-care clinic
in week 8–12. From LISA we collected information on marital
status and highest level of maternal education at start of
pregnancy.
Maternal asthma – diagnosis and medication. We used
multiple registers to identify individuals with asthma in the study
population. In the Medical Birth Register, a tick-box for self-
reported asthma/lung disease ever is indicated by the midwife at
antenatal care admission in early pregnancy. From the National
Patient Register we obtained information on specialist care visits
with a recently validated recorded diagnosis of asthma (ICD-10
codes J45, J46) twelve months before and during pregnancy [25].
Information on dispensed asthma medication before and during
pregnancy was obtained from ATC-codes (Anatomical Therapeu-
tic Chemical Classification) R03 (inhaled corticosteroids (ICS),
short-acting b2-agonists (SABA), long-acting b2-agonists (LABA),
leukotriene receptor antagonist (LTRA), anticholinergic inhalers,
sodium chromoglycate, theophylline and omalizumab) and H02
(oral corticosteroids) in the Prescribed Drug Register. Having had
asthma medication dispensed at least twice during the year before
pregnancy until birth date was used as a proxy for an asthma
diagnosis. We excluded oral b2-agonists (ATC code R03CC) since
this is not only prescribed for asthma but sometimes for premature
contractions. Our main exposure was asthma recorded in any of
the three registers the Medical Birth Register, the National Patient
Register or the Prescribed Drug Register.
In order to assess usage of asthma medication during different
pregnancy trimesters, midwife reports were extracted from the
Medical Birth Register along with gestational week of medication
start and discontinuation.
We defined asthma severity and control based on medication
use in the Prescribed Drug Register twelve months prior to
pregnancy modified from Firoozi et al [21]. Average daily dose of
ICS, SABA and two prescriptions per year of LABA, theophylline,
and LTRA, along with asthma diagnoses in the National Patient
Register inpatient part [26] and/or filled prescription of an oral
corticosteroid over 12 months were used to categorize the mothers
into mild or moderate/severe asthma that could be either
controlled or uncontrolled, Appendix S1. The severity index was
modified by changing the number of filled prescriptions for LABA,
theophylline and LTRA from six to two over a 12 months period
for adhering more to local prescription patterns.
Outcomes. All the outcome variables were collected from the
Medical Birth Register. Based on pregnancy and delivery ICD-10
codes recorded we could collect information on preeclampsia/
eclampsia (ICD-10: O14–15), gestational diabetes (ICD-10: O24),
haemorrhage during pregnancy (ICD-10: O46), premature
contractions (ICD-10: O47) premature rupture of membranes,
PROM (ICD-10: O42) and placental abruption (ICD-10: O45).
We also included the following labour information: dystocia
during labour, induced/spontaneous onset of labour, caesarean
section (elective or emergency caesarean section prior to onset of
labour, or emergency CS after onset of labour) and vaginal
instrumental delivery (ICD-10-codes O62, O66.5, O81, O82 for
forceps or vacuum extraction). Based on these, delivery mode was
categorized as: 1) Vaginal, non-instrumental delivery, 2) Elective
caesarean (before start of labour), 3) Vaginal instrumental delivery
and 4) Emergency caesarean section (prior to or after start of
labour).
For birth outcomes and post-partum characteristics we used
data on birth weight, gestational age, small (SGA)/large (LGA) for
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gestational age (birth weight .2 standard deviations below or
above reference curve for children of similar gestational age) [27],
Apgar at 5 minutes, information on haemorrhage after delivery
(ICD-10: O72), and asphyxia/hypoxia (ICD-10: P20–P21).
Statistical analysis
We used logistic and multinomial logistic regression analysis to
estimate odds ratios (OR) as the measure of association, with 95%
confidence intervals (CI) for the outcomes in relation to asthma in
any of the three registers as well as asthma medication in the
Medical Birth Register, asthma severity and asthma control the
year before pregnancy. We estimated both the crude ORs and
adjusted for maternal age, BMI, parity, smoking at start of
pregnancy, cohabitation/marital status, education and country of
birth. To account for the clustering of observations within women
with multiple deliveries the sandwich estimator for the standard
errors was used. The Holm-Bonferroni method was used to
evaluate what significant results from the primary analyses (i.e.
adjusted analyses of maternal asthma yes/no and each of the
outcome variables) there would be if applying an overall 5%
significance level for those tests, To test for effect modification of
asthma control by disease severity we included interaction terms in
the models and tested for significance with likelihood-ratio test.
STATA 12.1 was used for the analyses.
Permission for this study was obtained from the Regional
Ethical Review board, ‘‘Regionala etikpro¨vningsna¨mnden –
EPN’’, in Stockholm, Sweden. In accordance with their decision,
we did not obtain informed consent from participants involved in
the study. All data were made anonymous prior to analyses.
Results
In this register-based cohort study, 284 214 pregnancies were
completed in 266 045 women during the study period. The
majority of women gave birth to only one child, but some women
had two (18 003 women) or three (83 women) pregnancies within
the period. Asthma was recorded for 26 586 (9.4%) of all
pregnancies.
Maternal characteristics in relation to maternal asthma in any of
the three registers are shown in Table 1. Compared to women
without asthma, those with asthma were slightly younger (16.0%
versus 14.6% below 25 years of age), had higher BMI, and were
more often primiparous and smokers, more often born in Sweden,
less often living with the baby’s father and had lower education.
Maternal asthma was associated with an increased risk of almost
all pregnancy complications, Table 2. For example, there was a
15% increased odds of preeclampsia or eclampsia (95% CI 1.06–
1.24) in the group with maternal asthma and an 34% increased
odds of haemorrhage during pregnancy (95% CI 1.12–1.60) and
premature contractions which were increased by 52% (95% CI
1.29–1.80). There were also increased odds for adverse birth
outcomes, including low birth weight and low gestational age.
After adjusting for multiple testing most statistically significant
associations remained except for lowest birth weight category and
LGA. Subanalyses using asthma medication or diagnosis in the
three different registers separately showed similar estimates, data
not tabulated.
Among women with asthma in any of the health registers, 31%
also had asthma medication recorded in the Medical Birth
Register during pregnancy and only 0.4% had asthma medication
during pregnancy if no asthma was noted in the registers,
Figure 1a. According to the severity index, 13 034 (4.6% of the
population) had asthma the year prior to conception. Of those,
32% were classified as mild controlled asthma, 37% as mild
uncontrolled, 12% as moderate controlled, 15% as moderate
uncontrolled, 0.6% as severe controlled and 4% as severe
uncontrolled asthma. Among the 8962 women with mild asthma
according to the severity index, 31% had asthma medication noted
in the Medical Birth Register and 65% of the 4072 women with
moderate or severe asthma, Figure 1b.
In the Medical Birth Register, treatment with asthma drugs was
most commonly already present at the start of pregnancy or
initiated during the first trimester, Figure 2. Most women
continued their medication throughout the whole pregnancy or
ended medication during the third trimester. Short-acting b2-
agonists (SABA) and inhaled corticosteroids (ICS) medication were
slightly more often discontinued during pregnancy compared to
other asthma medications (LABA and LTRA). We were not able
to assess whether this group of women were at higher risk of
pregnancy complications than those who did not discontinue.
There was however an increased risk of adverse pregnancy
outcomes in women with asthma medication noted in the Medical
Birth Register, similar to the main results.
For analyses on the association between asthma severity
(moderate/severe asthma with mild asthma as reference) and
adverse outcomes, no increased risks for the described pregnancy
outcomes were seen, Table 3. For the association between labour
characteristics and birth outcomes there were significant findings
for vaginal instrumental delivery, emergency CS, and the children
born to women with moderate/severe asthma were significantly
smaller compared to those born to women with mild asthma.
In analyses of asthma control (uncontrolled versus controlled),
for most outcomes we couldn’t detect significant differences.
However, pregnant women with uncontrolled asthma were at
increased risk of instrumental vaginal delivery (OR 1.17 95% CI
1.03–1.34) compared to women with controlled asthma. An
uncontrolled asthma also seemed to decrease the risk of premature
contractions (OR 0.63, 95% CI 0.42–0.95) and low Apgar (OR
0.72 95% CI 0.52–0.99). There was significant effect modification
(interaction) between asthma control and severity for premature
rupture of the membranes (p = 0.007) and gestational age
(p = 0.011). Uncontrolled asthma reduced the odds for premature
rupture of the membranes for women with mild asthma (OR 0.65
95% CI 0.47–0.90), but not moderate/severe (OR 1.44 95% CI
0.88–2.35). For gestational age, there was a significantly increased
risk of giving birth in week 37–38 if having uncontrolled asthma
(OR 1.29 95% CI 1.07–1.56) among women with moderate/
severe asthma but not among those with mild asthma, not shown
in table.
Discussion
In this population-based cohort study of 284 214 pregnancies,
we found that maternal asthma is a risk factor for a number of
adverse pregnancy and labour outcomes such as preeclampsia/
eclampsia and caesarean section, and perinatal outcomes such as
SGA. We also showed an increased risk of some adverse outcomes
with increasing asthma severity the year prior to pregnancy,
including instrumental delivery, emergency caesarean section,
birth weight 2000–3499 grams and SGA. The adverse impact of
asthma in pregnancy on most outcomes is striking. Although
increased risks of haemorrhage during pregnancy, premature
contractions, placental abruption and SGA have been observed in
some previous studies [5,6,9,12–14,28–30], the novelty with our
results is the consistency in risk increases for women with asthma
before and during pregnancy across all pregnancy and labour
characteristics, as well as most perinatal outcomes. This has not
Asthma during Pregnancy
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been previously shown and has important public health implica-
tions.
We observed higher rate of caesarean section in asthma patients
which is in agreement with most previous studies [9,10,13,31].
Higher rate of CS has also been observed in other chronic
conditions [32–34] and it has been proposed that the higher rates
of delivery interventions might be related to foetal stress associated
with the underlying disease. However, we did not find an
Table 1. Background characteristics of study population of 284 214 pregnancies by asthma status.
Asthma* No Asthma* Yes
n=257 628 n=26 586
n(%) n(%)
Maternal Characteristics
Age
#19 4312 (1.7) 519 (2.0)
20–24 33 316 (12.9) 3721 (14.0)
25–29 73 744 (28.6) 7626 (28.7)
30–34 89 948 (34.9) 8973 (33.8)
.34 56 308 (21.9) 5747 (21.6)
BMI
,18,5 5763 (2.2) 518 (1.9)
18,5–24,9 145 226 (56.4) 13 288 (50.0)
25–29,9 57 913 (22.5) 6740 (25.4)
$30 26 471 (10.3) 4222 (15.9)
Missing 22 255 (8.6) 1818 (6.8)
Parity
1 149 334 (58.0) 16 065 (60.4)
2–3 94 090 (36.5) 8937 (33.6)
$4 14 204 (5.5) 1584 (6.0)
Sex of offspring
Girl 124 881 (48.5) 12 966 (48.8)
Boy 132 747 (51.5) 13 620 (51.2)
Cigarettes smoked/day
0 229 737 (89.2) 23 452 (88.2)
1–9 12 774 (5.0) 1821 (6.8)
.9 3684 (1.4) 620 (2.3)
Missing 11 433 (4.4) 693 (2.6)
Country of birth
Sweden 198 585 (77.1) 22 945 (86.3)
Denmark, Norway, Finland, Iceland 4051 (1.6) 411 (1.5)
Other countries 54 845 (21.3) 3221 (12.1)
Missing 147 (0.1) 9 (0.0)
Cohabitation/marital status
Living with baby’s father, married 105 247 (40.9) 9788 (36.8)
Living with baby’s father, unmarried 124 405 (48.3) 14 107 (53.1)
Not living with baby’s father 13 673 (5.3) 1840 (6.9)
Missing 14 303 (5.6) 851 (3.2)
Mother’s education level
#9 years 27 491 (10.7) 3141 (11.8)
10–12 years 96 841 (37.6) 10 870 (40.9)
13–14 years 30 287 (11.8) 3124 (11.8)
$15 years 92 756 (36.0) 9038 (34.0)
Missing 10 253 (4.0) 413 (1.6)
*Asthma recorded in the Swedish Medical Birth Register, asthma diagnosis in the Swedish National Patient Register and/or asthma medication suspended at least twice
according to the Swedish Prescribed Drug Register.
doi:10.1371/journal.pone.0104755.t001
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Table 2. Associations between maternal asthma and pregnancy characteristics, labour characteristics and perinatal outcomes in a
cohort of 284 214 pregnancies, reported as unadjusted and adjusted OR with 95% CI, all estimated by multinomial logistic
regression.
Number of
pregnancies Asthma1 Unadjusted OR (95% CI) Adjusted{ OR (95% CI) P-values adjusted
N (%) n(%)
Pregnancy Characteristics
Preeclampsia or eclampsia 7797 (2.7) 915 (3.4) 1.30 (1.21–1.39) 1.15 (1.06–1.24) ,0.001*
Gestational diabetes 4804 (1.7) 534 (2.0) 1.22 (1.10–1.34) 1.09 (0.99–1.20) 0.066
Haemorrhage during pregnancy 1341 (0.5) 151 (0.6) 1.23 (1.03–1.48) 1.34 (1.12–1.60) 0.001*
Premature contractions 1497 (0.5) 211 (0.8) 1.59 (1.37–1.85) 1.52 (1.29–1.80) ,0.001*
Premature rupture of membranes 4630 (1.6) 544 (2.0) 1.30 (1.19–1.41) 1.30 (1.18–1.43) ,0.001*
Placental abruption 1053 (0.4) 136 (0.5) 1.44 (1.21–1.71) 1.44 (1.18–1.75) ,0.001*
Labour Characteristics
Labour dystocia 29 523 (10.4) 3040 (11.4) 1.13 (1.08–1.17) 1.10 (1.06–1.15) ,0.001*
Mode of delivery
Vaginal non-instrumental delivery 213 687 (75.2) 18 916 (71.2) Ref. Ref.
Elective CS (before start of labour) 19 396 (6.8) 2191 (8.2) 1.31 (1.25–1.38) 1.29 (1.22–1.36) ,0.001*
Vaginal instrumental delivery 21 792 (7.7) 2105 (7.9) 1.10 (1.05–1.15) 1.11 (1.06–1.17) ,0.001*
Emergency CS prior to or after start of
labour
27 632 (9.7) 3177 (11.9) 1.34 (1.29–1.39) 1.29 (1.23–1.34) ,0.001*
Missing 1707 (0.6) 197 (0.7)
Haemorrhage after delivery 14 765 (5.2) 1413 (5.3) 1.03 (0.97–1.08) 1.03 (0.97–1.09) 0.358
Birth outcome and post-partum
Birth weight, grams
#1999 3809 (1.3) 370 (1.4) 1.08 (0.96–1.20) 1.15 (1.02–1.29) 0.034
2000–2499 5811 (2.0) 637 (2.4) 1.23 (1.13–1.34) 1.32 (1.20–1.45) ,0.001*
2500–2999 30 118 (10.6) 3109 (11.7) 1.15 (1.10–1.20) 1.29 (1.23–1.34) ,0.001*
3000–3499 92 210 (32.4) 8615 (32.4) 1.03 (1.00–1.06) 1.12 (1.09–1.16) ,0.001*
$3500 151 827 (53.4) 13 810 (51.9) Ref. Ref.
Missing 439 (0.2) 45 (0.2)
Gestational age, weeks
#31 2398 (0.8) 221 (0.8) 1.03 (0.89–1.18) 1.05 (0.90–1.22) 0.671
32–34 3489 (1.2) 371 (1.4) 1.20 (1.08–1.35) 1.19 (1.06–1.33) 0.002*
35–36 8757 (3.1) 1030 (3.9) 1.35 (1.26–1.44) 1.30 (1.21–1.39) ,0.001*
37–38 54 084 (19.0) 5601 (21.1) 1.17 (1.13–1.21) 1.18 (1.13–1.22) ,0.001*
39–40 145 298 (51.1) 13 061 (49.1) Ref. Ref.
$41 69 993 (24.6) 6293 (23.7) 1.00 (0.97–1.03) 0.97 (0.94–1.01) 0.165
Missing 195 (0.1) 9 (0.0)
Small for gestational age
Yes 6722 (2.4) 714 (2.7) 1.16 (1.07–1.25) 1.23 (1.13–1.33) ,0.001*
Missing 625 (0.2) 54 (0.2)
Large for gestational age
Yes 9639 (3.4) 977 (3.7) 1.10 (1.03–1.17) 0.93 (0.86–0.99) 0.035
Missing 625 (0.2) 54 (0.2)
Apgar at 5 minutes ,7 3322 (1.3) 384 (1.4) 1.10 (0.99–1.23) 1.08 (0.96–1.20) 0.198
Asphyxia or hypoxia 2873 (1.0) 297 (1.1) 1.12 (0.99–1.26) 1.07 (0.94–1.22) 0.291
In the unadjusted analyses n = 26 586 pregnancies were included in the asthma group. In the adjusted analyses n = 24 203 pregnancies were included in the asthma
group.
1Asthma recorded in the Swedish Medical Birth Register, asthma diagnosis in the Swedish National Patient Register and/or asthma medication suspended at least twice
according to the Swedish Prescribed Drug Register.
{Adjusted for age, BMI, parity, smoking at antenatal care admission, country of birth, cohabitation/marital status and level of education.
*Significant after having adjusted for multiple hypotheses testing using the Holm-Bonferroni method.
doi:10.1371/journal.pone.0104755.t002
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association between asthma and low Apgar score or child hypoxia
or asphyxia in the registers. It is possible that women with chronic
disease in general are more likely to undergo surgery for a medical
reason or because of health care professionals’ assumption that
vaginal delivery is associated with more complications [35].
We did not identify asthma as a risk factor for preterm delivery
,32 weeks which is consistent with one previous study [8]. There
was however an increased risk of late preterm birth (GA 32–36
weeks). In the past, much focus has been on infant mortality and
morbidity in the very or extremely premature children but it is
now clear that even moderate or late prematurity are risk factors
for the child [36].
Some speculate that increased risks of preterm delivery among
women with asthma may be due to similarities between bronchial
and uterine smooth muscle hyperresponsiveness [30]. The
association between maternal asthma in pregnancy and adverse
outcomes may be caused by periods of intermittent hypoxia during
pregnancy affecting oxygenation of placental and cord blood
which in turn has a negative influence on the foetus. Such an
interpretation is supported by the finding of a correlation between
low FEV1 during pregnancy and intrauterine growth retardation
[37]. This hypothesis would also be supported if there were higher
risk of pregnancy complications in women who discontinue their
asthma medication during pregnancy. However we were not able
to show this, perhaps due to the fact that in some women asthma
improves during pregnancy [38]. There was an increased risk of
adverse pregnancy outcomes such as placental abruption in
women with asthma medication noted in the Medical Birth
Register and hypoxia in the placenta could be a mechanism for
abruption [39].
In separate analyses using asthma medication and diagnoses
from the three separate registers, we observed increased risks of
adverse outcomes similar to that of the overall analysis. This would
suggest that asthma as such plays a key role in the adverse
outcomes.
Women with uncontrolled asthma were at increased risk of
instrumental vaginal delivery but also had decreased risk of
premature contractions and low Apgar score and there was a slight
interaction between asthma control and severity. These might be
random findings or due to the overrepresented mild asthma group,
but the lower risk of premature contractions might also be due to
use of high doses of short acting beta agonists which are known to
inhibit contractions of the uterus [40]. The findings should be
further investigated in a clinical prospective cohort study on
asthma severity, control and medication, where also discontinu-
ation of medication can be further assessed.
The present study is the largest prospective to date with several
strengths. Firstly, it is a population-based, longitudinal register
based study in a unified health care environment with recording in
medical registers of 280 000 singleton pregnancies in Sweden. In a
cohort of the total population, we have the advantage that the
results are representative and thus easily generalisable to the
general population. Secondly, information on exposures and
outcomes were prospectively collected, which precludes recall bias.
Figure 1. Asthma medication in the Medical Birth Register. a) Proportion of women with asthma medication recorded in the Medical Birth
Register if asthma reported in the Medical Birth Register, National Patient Register or the Prescribed Drug Register. b) Proportion of women with
asthma medication in the Medical Birth Register among those with no, mild and moderate/severe asthma according to the modified Firoozi severity
index.
doi:10.1371/journal.pone.0104755.g001
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Thirdly, the asthma diagnosis was established by applying
predetermined asthma criteria to the National Patient Register
(covers inpatient and outpatient visits but not visits to general
practitioners), the Prescribed Drug Register (full coverage of all
dispensed asthma medication); and the Swedish Medical Birth
Register (covers approximately 99% of the pregnancies.22 weeks
[23,41]). In addition, the large sample gave us high statistical
power.
There are also inherent limitations in register based studies.
First, there may be residual confounding due to factors not
recorded in the registers. We lack information on genetic factors,
many pregnancy associated factors (e.g. maternal diet and passive
smoking, physical activity or alcohol usage during pregnancy), and
other factors related to both maternal asthma and pregnancy
outcomes (e.g. health care utilisation patterns) [42]. Secondly,
some posts in the Medical Birth Register are derived from
automatic linking from other national registers whereas other
variables such as asthma and medication rely on self-reporting to
the midwife. Stephansson et al recently showed that the rate of
reporting of medication in the Medical Birth Register is higher for
more severe and chronic diseases. For asthma the agreement
between the Prescribed Drug Register and the Medical Birth
Register is around 58% [43]. We had however also access to
maternal asthma diagnosis in the National Patient Register as well
as medication in the Prescribed Drug Register, and detected
higher estimates for the association between maternal asthma
during pregnancy and outcomes in the National Patient Register
and Prescribed Drug Register compared to the Medical Birth
Register. Thirdly, asthma severity was assessed with an index
developed in another country (Canada) and although Sweden and
Canada are similar in many ways it’s not certain the index validity
is the same in Sweden. Our results indicate a need for increased
awareness among midwives and obstetricians on the adverse
effects of maternal asthma during pregnancy.
By increasing awareness of the population with maternal
asthma before and during pregnancy and by doing so ensuring
proper management, pregnancy and labour characteristics and
perinatal outcomes would most likely improve. A study to test
clinical guidelines for asthma in early pregnancy with a possibility
of early asthma detection and asthma control intervention might
be useful to women who are at risks of pregnancy complications,
and a next step in further understanding the effects of the disease
in pregnancy.
In conclusion, maternal asthma during pregnancy is associated
with an increased risk of a number of serious pregnancy and
labour complications and adverse perinatal outcomes. There is
also an increased risk of a few adverse outcomes based on asthma
severity and control. Greater awareness and improved asthma
management would most likely improve outcomes.
Figure 2. Asthma medication during trimesters. Starting and ending of treatment with asthma drugs (short-acting b2-agonists, SABA; inhaled
corticosteroids, ICS and others (long-acting b2-agonists LABA and leukotriene receptor antagonist LTRA) in the Medical Birth Register.
doi:10.1371/journal.pone.0104755.g002
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Table 3. Associations between moderate/severe asthma according to the Firoozi index the year before pregnancy and perinatal
outcomes in a cohort of 284 214 pregnancies, mild asthma as reference.
Cases in mild
asthma group
Cases in moderate-
severe asthma group
Moderate/severe asthma
vs Mild asthma
Moderate/severe
asthma vs Mild
asthma
P-values
adjusted
n (%) n (%) Unadjusted OR (95% CI)
Adjusted* OR
(95% CI)
Pregnancy characteristics
Preeclampsia or eclampsia 319 (3.6) 159 (3.9) 1.10 (0.89–1.35) 1.01 (0.81–1.26) 0.927
Gestational diabetes 188 (2.1) 85 (2.1) 0.99 (0.76–1.30) 0.97 (0.73–1.30) 0.850
Haemorrhage during pregnancy 54 (0.6) 27 (0.7) 1.10 (0.70–1.73) 1.13 (0.70–1.83) 0.612
Premature contractions 72 (0.8) 29 (0.7) 0.89 (0.56–1.41) 0.92 (0.59–1.43) 0.715
Premature rupture of membranes 167 (1.9) 88 (2.2) 1.16 (0.90–1.50) 1.20 (0.92–1.57) 0.182
Placental abruption 44 (0.5) 19 (0.5) 0.95 (0.53–1.71) 0.80 (0.46–1.40) 0.444
Labour characteristics
Labour dystocia 1077 (12.0) 497 (12.2) 1.02 (0.91–1.14) 1.06 (0.94–1.19) 0.364
Mode of delivery
Vaginal, non-instrumental delivery 6394 (71.3) 2767 (68.0) Ref. Ref.
Elective CS (before start of labour) 732 (8.2) 358 (8.8) 1.13 (0.99–1.30) 0.99 (0.85–1.14) 0.861
Vaginal instrumental delivery 742 (8.3) 373 (9.2) 1.16 (1.01–1.34) 1.19 (1.03–1.37) 0.020
Emergency CS prior to or after onset of labour 1024 (11.4) 537 (13.2) 1.21 (1.08–1.36) 1.18 (1.04–1.33) 0.012
Missing 70 (0.8) 37 (0.9)
Haemorrhage after delivery 499 (5.6) 222 (5.5) 0.98 (0.83–1.15) 1.03 (0.86–1.24) 0.728
Birth outcome and post-partum
Birth weight, grams
#1999 123 (1.4) 56 (1.4) 1.07 (0.77–1.48) 0.99 (0.68–1.44) 0.964
2000–2499 184 (2.1) 113 (2.8) 1.44 (1.14–1.82) 1.45 (1.13–1.86) 0.004
2500–2999 966 (10.8) 539 (13.2) 1.31 (1.17–1.47) 1.39 (1.22–1.57) ,0.001
3000–3499 2907 (32.4) 1328 (32.6) 1.07 (0.99–1.16) 1.14 (1.04–1.25) 0.004
$3500 4766 (53.2) 2031 (49.9) Ref. Ref.
Missing 16 (0.2) 5 (0.1)
Gestational age, weeks
#31 82 (0.9) 38 (0.9) 1.03 (0.69–1.54) 0.92 (0.59–1.42) 0.696
32–34 107 (1.2) 47 (1.2) 0.98 (0.68–1.40) 0.96 (0.66–1.39) 0.813
35–36 318 (3.5) 154 (3.8) 1.08 (0.88–1.32) 1.04 (0.84–1.28) 0.719
37–38 1802 (20.1) 863 (21.2) 1.07 (0.96–1.18) 1.05 (0.94–1.16) 0.399
39–40 4399 (49.1) 1978 (48.6) Ref. Ref.
$41 2254 (25.2) 992 (24.4) 0.98 (0.89–1.07) 0.99 (0.90–1.09) 0.824
Missing 0 (0.0) 0 (0.0)
Small for gestational age
Yes 204 (2.3) 153 (3.8) 1.68 (1.35–2.08) 1.71 (1.34–2.17) ,0.001
Missing 16 (0.2) 5 (0.1)
Large for gestational age
Yes 375 (4.2) 127 (3.1) 0.74 (0.60–0.91) 0.65 (0.52–0.81) ,0.001
Missing 16 (0.2) 5 (0.1)
Apgar at 5 minutes ,7 132 (1.5) 69 (1.7) 1.15 (0.86–1.54) 1.17 (0.86–1.59) 0.320
Asphyxia or hypoxia 110 (1.2) 53 (1.3) 1.06 (0.76–1.49) 1.12 (0.80–1.57) 0.495
Unadjusted and adjusted model (n = 249 006) estimated by multinomial logistic regression with OR and 95% CI. In unadjusted analyses n = 8962 were included in the
mild asthma group and n = 4072 in the moderate/severe group. In the adjusted analyses n = 7996 were included in the mild and n = 3646 in the moderate/severe group.
*Adjusted for age, BMI, parity, smoking at antenatal care admission, country of birth, cohabitation/marital status and level of education.
doi:10.1371/journal.pone.0104755.t003
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